A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

After starting therapy for psoriasis, Asempa usually has a follow-up visit at 3 to 4 months. Patient feedback at that point carries a lot of weight with respect to next steps.